SWOT Analysis
- S
- W
- O
- T
-
Strength (16)
This screener identifies stocks based on the CANSLIM methodology. It covers EPS and revenue growth, as well as institutional investor interest, RSI strength and other metrics. Not included in the metrics is new product introduction/new market entry. To follow this screener, set an alert.
-
Weakness (1)
Declining net cash flows
-
Opportunity (1)
FII / FPI or Institutions increasing their shareholding
-
Threats (1)
See all stocks where MFs decreased their stake last quarter. MFs decreasing their shareholding in a stock is considered negative for the stock.
- Stock passes majority of CANSLIM Investment criteria
- Strong Momentum: Price above short, medium and long term moving averages
- Companies with high TTM EPS Growth
- New 52 week high today
- Good quarterly growth in the recent results
- Effectively using its capital to generate profit - RoCE improving in last 2 years
- Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
- Efficient in managing Assets to generate Profits - ROA improving since last 2 year
- Growth in Net Profit with increasing Profit Margin (QoQ)
- Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
- Companies with Low Debt
- Annual Net Profits improving for last 2 years
- Companies with Zero Promoter Pledge
- Recent Results : Growth in Operating Profit with increase in operating margins (YoY)
- Negative to Positive growth in Sales and Profit with Strong Price momentum
- RSI indicating price strength
- FII / FPI or Institutions increasing their shareholding
Technical Analysis
Moving Averages
- 5 Day 1,976.0
- 10 Day 1,966.1
- 12 Day 1,962.0
- 20 Day 1,941.8
- 26 Day 1,925.2
- 50 Day 1,863.0
- 100 Day 1,766.0
- 200 Day 1,654.0
Current Price
- Bullish Moving Averages 16
- Bearish Moving Averages 0
Resistance and support
- First Resistance 2,043.7
- Second Resistance 2,077.9
- Third Resistance 2,117.7
- First Support 1,969.7
- Second Support 1,929.9
- Third Support 1,895.7
Company Financials
- Profit and loss statement
- Balance sheet
- Quarterly Result
- Ratio
- CAGR IN 10 YEARS
- 10.04%
- 17.28%
- 22.06%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 7,336.75 | 6,677.92 | 6,166.46 | 5,814.62 | 5,438.30 |
|
| Operating Profit | 1,751.82 | 1,245.51 | 1,079.93 | 914.27 | 1,241.25 |
|
| OP Profit Margin | 23.88 | 18.65 | 17.51 | 15.72 | 22.82 |
|
| Interest | 45.46 | 65.06 | 122.58 | 46.34 | 10.41 |
|
| Profit After Tax | 1,132.52 | 650.76 | 530.41 | 505.70 | 860.37 |
|
| Cash Profit | 1,471.95 | 1,212.99 | 871.21 | 734.34 | 1,120.90 |
|
| EPS | 44.64 | 25.65 | 20.91 | 19.93 | 33.91 |
|
- CAGR IN 10 YEARS
- 13.89%
- -9.37%
- 9.22%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| Equity | 25.37 | 25.37 | 25.37 | 25.37 | 25.37 |
|
| Reserve Surplus | 7,953.98 | 6,866.25 | 6,323.34 | 5,851.93 | 5,450.39 |
|
| TOT Debts | 295.22 | 906.23 | 1,151.82 | 1,440.38 | 776.41 |
|
| Gross Block | 5,036.64 | 4,387.79 | 4,165.82 | 3,889.09 | 3,364.68 |
|
| Capital Work In Progress | 459.37 | 489.65 | 175.20 | 123.02 | 297.15 |
|
| Cash Liquid Investment | 363.18 | 164.53 | 112.92 | 1,706.06 | 595.50 |
|
| Net Working Capital | 2,214.62 | 1,912.69 | 1,991.16 | 3,469.39 | 2,363.21 |
|
| Current Assets | 3,689.33 | 3,162.69 | 3,122.46 | 4,570.35 | 3,606.63 |
|
| Current Liabilities | 1,474.71 | 1,250.00 | 1,131.30 | 1,100.96 | 1,243.42 |
|
Jun 2026 (CR) |
Mar 2026 (CR) |
Dec 2025 (CR) |
Sep 2025 (CR) |
Jun 2025 (CR) |
||
|---|---|---|---|---|---|---|
| Sales | 2,119.24 | 1,814.35 | 1,845.18 | 1,930.32 | 1,746.90 |
|
| Gross Profit | 590.02 | 420.16 | 485.79 | 475.17 | 419.88 |
|
| Gross Profit Margins | 78.97 | 77.61 | 78.91 | 80.45 | 77.35 |
|
| Operating Profit | 577.64 | 400.76 | 477.48 | 464.71 | 406.92 |
|
| OP Profit Margin | 24.56 | 19.86 | 23.13 | 21.75 | 21.11 |
|
| Interest | 5.04 | 10.48 | 9.51 | 11.46 | 12.06 |
|
| Profit After Tax | 373.29 | 262.29 | 303.45 | 304.74 | 262.04 |
|
| Cash Profit | 447.90 | 332.60 | 372.02 | 371.60 | 325.17 |
|
| EPS | 14.71 | 11.54 | 11.96 | 12.01 | 10.33 |
|
- CAGR IN 10 YEARS
- 13.89%
- -9.37%
- 9.22%
Mar 2026 (CR) |
Mar 2025 (CR) |
Mar 2024 (CR) |
Mar 2023 (CR) |
Mar 2022 (CR) |
||
|---|---|---|---|---|---|---|
| PE | 35.91 | 58.53 | 59.23 | 40.65 | 31.29 |
|
| P/BV | 5.10 | 5.53 | 4.95 | 3.50 | 4.92 |
|
| MCAP Sales | 5.54 | 5.70 | 5.09 | 3.54 | 4.95 |
|
| Asset Turnover | 0.91 | 0.87 | 0.83 | 0.85 | 0.96 |
|
| EV/EBITDA | 21.99 | 29.49 | 27.24 | 19.79 | 20.94 |
|
| DEBT/EQUITY | 0.08 | 0.16 | 0.21 | 0.20 | 0.10 |
|
| ROE | 15.23 | 12.39 | 9.81 | 8.91 | 16.82 |
|
| ROCE | 19.48 | 17.21 | 14.12 | 11.67 | 19.15 |
|
Quick Results Snapshot
Q1FY27 Quarterly Result Announced for Ipca Laboratories Ltd.
Pharmaceuticals company Ipca Laboratories announced Q1FY27 results
Standalone Financial Highlights:
- Total Income for Q1FY27 stood at Rs 2,136.66 crore, representing a YoY increase of 20.58% compared to Rs 1,771.92 crore in Q1FY26 and a QoQ increase of 15.86% from Rs 1,844.23 crore in Q4FY26.
- Revenue from Operations reached Rs 2,119.24 crore in Q1FY27, up 21.31% YoY from Rs 1,746.90 crore in Q1FY26 and up 16.80% QoQ from Rs 1,814.35 crore in Q4FY26.
- Profit Before Tax (PBT) for Q1FY27 was Rs 515.41 crore, showing a YoY growth of 44.47% compared to Rs 356.75 crore in Q1FY26 and a QoQ growth of 47.32% from Rs 349.85 crore in Q4FY26.
- Net Profit after tax for the quarter was reported at Rs 373.29 crore in Q1FY27, growing by 42.46% YoY from Rs 262.04 crore in Q1FY26 and 42.32% QoQ from Rs 262.29 crore in Q4FY26.
- EBITDA margin (before forex gain/loss and other income) improved to 26.27% in Q1FY27 compared to 23.82% in Q1FY26.
- Other Income was Rs 17.42 crore in Q1FY27, a decrease of 30.38% YoY from Rs 25.02 crore in Q1FY26.
- Basic Earnings Per Share (EPS) stood at Rs 14.71 for Q1FY27, compared to Rs 10.33 in Q1FY26 and Rs 10.34 in Q4FY26.
Consolidated Financial Highlights:
- Total Income for Q1FY27 was Rs 2,813.36 crore, reflecting a YoY growth of 20.15% from Rs 2,341.51 crore in Q1FY26 and a QoQ growth of 13.34% from Rs 2,482.22 crore in Q4FY26.
- Revenue from Operations grew by 20.76% YoY to Rs 2,788.10 crore in Q1FY27, compared to Rs 2,308.85 crore in Q1FY26. It also increased by 16.73% QoQ from Rs 2,388.48 crore in Q4FY26.
- Profit Before Tax (PBT) for the quarter stood at Rs 572.08 crore in Q1FY27, up 73.09% YoY from Rs 330.51 crore in Q1FY26 and up 41.45% QoQ from Rs 404.45 crore in Q4FY26.
- Net Profit attributable to owners of the parent was reported at Rs 401.89 crore in Q1FY27, a growth of 72.33% YoY compared to Rs 233.21 crore in Q1FY26 and a growth of 34.38% QoQ from Rs 299.07 crore in Q4FY26.
- EBITDA margin (before forex gain/loss and other income) for Q1FY27 was 22.88%, compared to 18.39% in Q1FY26.
- Other Income was Rs 25.26 crore in Q1FY27, representing a YoY decrease of 22.66% from Rs 32.66 crore in Q1FY26.
- Basic Earnings Per Share (EPS) for Q1FY27 stood at Rs 15.84, against Rs 9.19 in Q1FY26 and Rs 13.31 in Q4FY26.
Business Highlights:
- Revenue Break-up by Products:
- Formulations: Total formulations revenue grew by 19% YoY to Rs 1,685.16 crore in Q1FY27. Domestic formulations contributed Rs 1,082.12 crore (up 13% YoY), while exports were Rs 603.04 crore (comprising Branded at Rs 143.27 crore, up 16% YoY; Institutional at Rs 119.75 crore, up 107% YoY; and Generics at Rs 340.02 crore, up 27% YoY).
- APIs: Total APIs revenue stood at Rs 423.72 crore in Q1FY27, marking a growth of 30% YoY. Domestic API sales were Rs 91.37 crore (up 20% YoY) and Export API sales were Rs 332.35 crore (up 33% YoY).
- Geographic Performance:
- Revenue from India was Rs 1,229.21 crore in Q1FY27, compared to Rs 1,083.17 crore in Q1FY26.
- Revenue from Outside India was Rs 1,558.89 crore in Q1FY27, compared to Rs 1,225.68 crore in Q1FY26.
- Other Developments: The Board of Directors, in their meeting held on June 26, 2026, resolved to amalgamate M/s. Krebs Biochemicals & Industries Ltd. with the company, with an appointed date of April 1, 2026. However, no effect for this amalgamation has been given in the unaudited financial results pending necessary consents/approvals.
Stocks Comparison
Table
Chart
Company name |
LTP |
Market cap (Cr) |
Return (1Y %) |
Risk (Std. Dev.) |
PE Ratio |
Financial Year |
|---|---|---|---|---|---|---|
| Ipca Laboratories Ltd | 2,009.60 | 50,984.40 | 53.26 | 0.07 | 37.10 | Mar 2026 |
| Sun Pharmaceutical Industries Ltd | 1,837.30 | 440,829.81 | 13.40 | 0.05 | 36.35 | Mar 2026 |
| Divis Laboratories Ltd | 9,375.00 | 248,876.79 | 54.92 | 0.11 | 85.02 | Mar 2026 |
| Torrent Pharmaceuticals Ltd | 4,840.00 | 184,098.04 | 36.40 | 0.04 | 84.76 | Mar 2026 |
| Zydus Lifesciences Ltd | 1,160.00 | 115,710.44 | 12.21 | 0.07 | 25.04 | Mar 2026 |
| Cipla Ltd | 1,394.50 | 112,655.86 | -10.59 | 0.06 | 33.02 | Mar 2026 |
| Laurus Labs Ltd | 1,954.00 | 105,577.01 | 118.58 | 0.11 | 96.89 | Mar 2026 |
| Aurobindo Pharma Ltd | 1,734.00 | 99,770.53 | 58.26 | 0.04 | 26.90 | Mar 2026 |
| Dr Reddys Laboratories Ltd | 1,185.00 | 98,909.61 | -9.64 | 0.06 | 30.71 | Mar 2026 |
| Lupin Ltd | 2,083.00 | 95,248.48 | 2.55 | 0.04 | 17.67 | Mar 2026 |
| Mankind Pharma Ltd | 2,300.70 | 95,029.28 | -10.49 | 0.06 | 46.30 | Mar 2026 |
| Glenmark Pharmaceuticals Ltd | 2,447.40 | 69,071.67 | 19.83 | 0.06 | 37.36 | Mar 2026 |
| Alkem Laboratories Ltd | 5,466.50 | 65,360.21 | -0.11 | 0.04 | 29.84 | Mar 2026 |
| Biocon Ltd | 385.00 | 62,743.22 | 8.65 | 0.08 | 150.39 | Mar 2026 |
| Abbott India Ltd | 27,270.00 | 57,948.75 | -11.95 | 0.05 | 35.89 | Mar 2026 |
| Anthem Biosciences Ltd | 928.50 | 52,305.97 | 7.40 | 0.09 | 91.36 | Mar 2026 |
| Gland Pharma Ltd | 2,961.90 | 48,874.56 | 49.07 | - | 43.30 | Mar 2026 |
| Glaxosmithkline Pharmaceuticals Ltd | 2,838.80 | 48,090.98 | 3.53 | 0.08 | 45.23 | Mar 2026 |
| Ajanta Pharma Ltd | 3,563.60 | 44,530.40 | 39.15 | 0.06 | 39.27 | Mar 2026 |
| J B Chemicals & Pharmaceuticals Ltd | 2,408.90 | 38,676.99 | 45.54 | 0.04 | 54.59 | Mar 2026 |
| Emcure Pharmaceuticals Ltd | 2,003.80 | 38,014.22 | 47.88 | 0.06 | 37.53 | Mar 2026 |
| Sai Life Sciences Ltd | 1,600.50 | 33,993.69 | 78.26 | 0.07 | 94.01 | Mar 2026 |
| Wockhardt Ltd | 2,086.10 | 33,897.49 | 34.74 | 0.17 | 81.91 | Mar 2026 |
| Neuland Laboratories Ltd | 22,840.00 | 29,303.47 | 41.37 | 0.12 | 58.96 | Mar 2026 |
| Acutaas Chemicals Ltd | 3,440.30 | 28,166.12 | 133.29 | 0.13 | 72.67 | Mar 2026 |
| Piramal Pharma Ltd | 208.16 | 27,713.34 | 2.48 | 0.10 | -88.14 | Mar 2026 |
| Granules India Ltd | 875.50 | 23,881.87 | 60.33 | 0.05 | 36.04 | Mar 2026 |
| Caplin Point Laboratories Ltd | 2,748.60 | 20,892.57 | 17.96 | 0.12 | 30.81 | Mar 2026 |
| Shilpa Medicare Ltd | 1,021.10 | 19,970.86 | 148.65 | 0.19 | 67.16 | Mar 2026 |
| ERIS Lifesciences Ltd | 1,321.30 | 18,311.01 | -19.85 | 0.05 | 27.50 | Mar 2026 |
| Pfizer Ltd | 4,002.40 | 18,310.07 | -23.07 | 0.06 | 24.90 | Mar 2026 |
| OneSource Specialty Pharma Ltd | 1,594.90 | 18,289.18 | -13.11 | 0.15 | -376.29 | Mar 2025 |
| Alivus Life Sciences Ltd | 1,430.80 | 17,566.14 | 52.37 | - | 29.13 | Mar 2026 |
| Jubilant Pharmova Ltd | 1,065.40 | 16,971.82 | -4.10 | 0.07 | 48.37 | Mar 2026 |
| Astrazeneca Pharma India Ltd | 6,751.50 | 16,878.75 | -26.12 | 0.07 | 99.50 | Mar 2026 |
| Cohance Lifesciences Ltd | 438.00 | 16,757.76 | -54.67 | - | 286.31 | Mar 2026 |
| Alembic Pharmaceuticals Ltd | 845.75 | 16,624.33 | -13.53 | 0.07 | 24.11 | Mar 2026 |
| Concord Biotech Ltd | 1,494.40 | 15,633.85 | -8.63 | - | 57.28 | Mar 2026 |
| Natco Pharma Ltd | 813.40 | 14,568.80 | -5.12 | 0.09 | 12.74 | Mar 2026 |
| Marksans Pharma Ltd | 320.15 | 14,508.04 | 78.62 | 0.14 | 27.81 | Mar 2026 |
| Strides Pharma Science Ltd | 1,219.80 | 11,243.23 | 37.79 | 0.07 | 17.72 | Mar 2026 |
| Viyash Scientific Ltd | 249.65 | 10,997.59 | 30.57 | 0.12 | 41.24 | Mar 2026 |
| Blue Jet Healthcare Ltd | 575.25 | 10,888.08 | -17.63 | 0.17 | 46.35 | Mar 2026 |
| Procter & Gamble Health Ltd | 5,503.50 | 9,135.47 | -13.42 | 0.08 | 25.59 | Mar 2026 |
| Aarti Pharmalabs Ltd | 820.40 | 7,439.37 | -10.67 | - | 34.91 | Mar 2026 |
| Sanofi India Ltd | 3,087.40 | 7,110.28 | -38.88 | 0.08 | 21.96 | Dec 2025 |
| Senores Pharmaceuticals Ltd | 1,402.60 | 6,459.48 | 103.50 | 0.10 | 49.48 | Mar 2025 |
| Jeena Sikho Lifecare Ltd | 510.40 | 6,344.31 | -39.09 | 0.11 | 26.81 | Mar 2026 |
Corporate Action
- Announcement
- Board Meeting
- Dividend
- Split
- Rights
- Events
| Ex-Date | Purpose | Notes |
|---|---|---|
| 2026-08-13 | Quarterly Results | |
| 2026-05-29 | Audited Results & Dividend | |
| 2026-02-13 | Quarterly Results | |
| 2025-11-13 | Quarterly Results | |
| 2025-08-11 | Quarterly Results | |
| 2025-05-29 | Audited Results & Final Dividend | |
| 2025-02-13 | Quarterly Results | |
| 2024-11-14 | Quarterly Results & Interim Dividend | |
| 2024-09-30 | Others | |
| 2024-08-13 | Quarterly Results | |
| 2024-05-29 | Audited Results & Final Dividend | |
| 2024-02-14 | Quarterly Results | |
| 2023-11-10 | Quarterly Results & Interim Dividend | |
| 2023-08-10 | Quarterly Results | |
| 2023-05-29 | Audited Results | |
| 2023-02-14 | Quarterly Results | |
| 2022-11-11 | Quarterly Results & Interim Dividend | |
| 2022-08-10 | Quarterly Results | |
| 2022-05-24 | Audited Results & Amalgamation | |
| 2022-02-14 | Quarterly Results | |
| 2021-11-13 | Qtr Results, Int. Dividend & Stock Split | |
| 2021-08-05 | Quarterly Results | |
| 2021-05-28 | Audited Results | |
| 2021-02-04 | Quarterly Results | |
| 2020-11-07 | Quarterly Results & Interim Dividend | |
| 2020-09-02 | Preferential Issue of shares | |
| 2020-08-10 | Quarterly Results | |
| 2020-06-16 | Audited Results | |
| 2020-02-12 | Quarterly Results | |
| 2019-11-07 | Quarterly Results | |
| 2019-09-26 | Issue Of Warrants | |
| 2019-08-13 | Quarterly Results | |
| 2019-05-29 | Audited Results & Final Dividend | |
| 2019-02-12 | Quarterly Results | |
| 2018-11-14 | Quarterly Results | |
| 2018-08-09 | Quarterly Results | |
| 2018-05-29 | Audited Results & Dividend | |
| 2018-02-07 | Quarterly Results | |
| 2017-11-14 | Quarterly Results | |
| 2017-08-11 | Quarterly Results | |
| 2017-05-28 | Audited Results & Dividend | |
| 2017-04-25 | Others | To consider grant of options under Ipca Laboratories Ltd. - Employees Stock Option Scheme - 2014 (ESOS) as sanctioned by the shareholders at the 64th A.G.M of the Com. |
| 2017-02-10 | Quarterly Results | |
| 2016-11-11 | Quarterly Results | |
| 2016-08-11 | Quarterly Results | |
| 2016-05-30 | Audited Results | |
| 2016-02-08 | Quarterly Results | |
| 2015-10-30 | Quarterly Results | |
| 2015-07-30 | Quarterly Results | |
| 2015-05-30 | Audited Results & Dividend | |
| 2015-02-07 | Quarterly Results | |
| 2014-11-10 | Quarterly Results | |
| 2014-07-31 | Quarterly Results | |
| 2014-05-29 | Audited Results & Final Dividend | |
| 2014-01-28 | Quarterly Results | |
| 2013-10-24 | Quarterly Results & Interim Dividend | |
| 2013-07-30 | Quarterly Results | |
| 2013-05-30 | Audited Results & Final Dividend | |
| 2013-01-30 | Quarterly Results & ESOP | To consider : Allotment of 48,750 equity shares of Rs. 2/- each on exercise of options under Ipca Laboratories Ltd - Employees Stock Option Scheme - 2006 (ESOS). |
| 2012-10-25 | Quarterly Results & Interim Dividend | |
| 2012-07-31 | Quarterly Results | |
| 2012-05-29 | Audited Results & Final Dividend | |
| 2012-05-16 | Others | 1. The order passed by the Hon'ble High Court of Judicature at Bombay and Hon'ble High Court of Gujarat approving the Scheme of Amalgamation of M/s. Tonira Pharma Ltd. with the Company. |
| 2012-04-13 | Appointment of Additional Director | The Board has appointed Mr. Dev Parkash Yadava as an Additional Director of the Company with immediate effect. |
| 2012-01-31 | Quarterly Results & 2nd Interim Dividend | |
| 2012-01-20 | Employees Stock Option Plan | The Board has alloted of 1,21,250 fully paid-up Equity Shares of Rs. 2/- each of the Company @ Rs. 63/- per Equity Share to whom options were granted on October 29, 2007 & November 11, 2008. |
| 2011-10-31 | Quarterly Results & Interim Dividend | |
| 2011-09-17 | To consider the Amalgamation | Inter-alia, to consider the Amalgamation / Merger of Tonira Pharma Limited with the Company. |
| 2011-07-28 | Quarterly Results | |
| 2011-05-24 | Audited Results & Final Dividend | |
| 2011-01-25 | Qtrly Results, 3rd Intrm Dividend & ESOP | For allotment of Equity Shares on exercise of options under Ipca Laboratories Ltd - Employees Stock Option Scheme - 2006 (ESOS). |
| 2010-10-22 | Quarterly Results & Interim Dividend | |
| 2010-07-29 | Quarterly Results | |
| 2010-05-28 | Audited Results & Final Dividend | |
| 2010-02-25 | To fix record date for Stock split | inter alia, to fix the 'Record Date' for deciding the Members entitlement of sub-divided Shares. |
| 2010-01-21 | Qtr Results, Int.Dividend & Stock Split | To consider the stock split of 5 Equity Shares of Rs. 2/- each for every 1 Equity Share of Rs. 10/- each & to allot of 14,250 fully paid-up Equity Shares of Rs 10/- each @ Rs. 315/- per Equity Share. |
| 2009-12-10 | Employees Stock Option Plan & Others | The Board has allotted 95,500 Equity Shares of Rs. 10/- each under the followings: 1. 77,250 fully paid-up Equity Shares of Rs. 10/- each. 2. 18,250 fully paid-up Equity Shares of Rs. 10/- each. |
| 2009-11-03 | Others | inter-alia, to consider closure of the on going Buy-back of own fully paid Equity Shares of the Company from open market purchase through Stock Exchanges. |
| 2009-10-27 | Quarterly Results & Interim Dividend | |
| 2009-07-30 | Quarterly Results | |
| 2009-05-28 | Audited Results & Final Dividend | |
| 2009-01-22 | Quarterly Results & Interim Dividend | |
| 2008-11-11 | Buy Back of Shares & ESOP | To allot 57,000 options to selected permanent employees of the Co. under Ipca Laboratories Ltd ESOS & to buy back of Company's own fully paid-up equity shares of Rs 10/- each from open market. |
| 2008-10-31 | Qtr. Results, Intrm. Dividend & ESOP | |
| 2008-10-30 | Others | To accept the resignation by Shri. Gaurav Mathur from the directorship of the Company & to appoint Shri. Kumar Krishnan Iyer as an Additional Director of the Company. |
| 2008-07-25 | Quarterly Results | |
| 2008-05-29 | Audited Results & Dividend | |
| 2008-01-19 | Quarterly Results | |
| 2007-10-29 | Employees Stock Option Plan | |
| 2007-07-20 | Quarterly Results | |
| 2007-05-25 | Audited Results & Final Dividend | |
| 2007-01-23 | Quarterly Results | |
| 2006-10-18 | Qtr. Results, Dividend & Int. Dividend | |
| 2006-09-23 | To consider grant of options | To consider grant of options to selected permanent employees and Directors. |
| 2006-07-28 | Quarterly Results | |
| 2006-05-30 | Accounts, Final Dividend & ESOS | |
| 2006-01-19 | Quarterly Results | |
| 2005-10-28 | Quarterly Results & Interim Dividend | |
| 2005-08-12 | Accounts/Amalgamation | To consider and take on record Order of the Board for Industrial & Financial Reconstruction (BIFR) ordering the amalgamation with the Company of Innotech Pharma Ltd (wholly owned subsidiary). |
| 2005-07-29 | Quarterly Results | (Revised) |
| 2005-06-28 | Final Dividend & Accounts | |
| 2005-01-29 | Quarterly Results | |
| 2004-12-25 | Others | To fix the record date for members entitlement of Bonus shares. |
| 2004-10-27 | Qtr Results, I. Dividend & Bonus issue | |
| 2004-07-27 | Quarterly Results | |
| 2004-06-29 | Accounts & Second Interim Dividend | |
| 2004-02-27 | Others | E.G.M. To consider merger of Infotech Pharma Ltd. with the company. |
| 2004-01-30 | Quarterly Results | |
| 2003-10-18 | Quarterly Results | |
| 2003-07-24 | Quarterly Results | |
| 2003-06-12 | Dividend & Accounts | |
| 2003-01-25 | Quarterly Results | |
| 2002-10-24 | Quarterly Results | |
| 2002-07-19 | Quarterly Results | |
| 2002-06-11 | Accounts & Dividend | |
| 2002-03-04 | Interim Dividend | (Revised) |
| 2002-01-30 | Quarterly Results and nine months | |
| 2001-11-03 | Quarterly Results & Half Yearly Results | (Revised) |
| 2001-07-26 | Quarterly Results | |
| 2001-05-10 | Dividend & Accounts | |
| 2001-01-25 | Quarterly Results | |
| 2000-10-19 | Quarterly Results | |
| 2000-06-22 | Accounts | |
| 2000-03-23 | Interim Dividend | |
| 2000-01-31 | Quarterly Results | |
| 1999-10-28 | Quarterly Results & Interim Dividend | |
| 1999-07-28 | Quarterly Results | |
| 1999-01-25 | Quarterly Results | |
| 1998-10-28 | Half Yearly Results & Interim Dividend | |
| 1998-06-25 | Accounts & Final Dividend | |
| 1997-10-21 | Half Yearly Results & Interim Dividend |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| 2026-08-07 | 6 | FINAL | 2026-08-07 | Equity Share |
| 2025-08-05 | 2 | FINAL | 2025-08-05 | Equity Share |
| 2024-11-25 | 2 | INTERIM | 2024-11-25 | Equity Share |
| 2024-08-06 | 2 | FINAL | Equity Share | |
| 2023-11-22 | 2 | INTERIM | 2023-11-22 | Equity Share |
| 2022-11-22 | 4 | INTERIM | 2022-11-23 | Equity Share |
| 2021-11-22 | 8 | INTERIM | 2021-11-23 | Equity Share |
| 2020-11-13 | 8 | INTERIM | 2020-11-17 | Equity Share |
| 2020-02-18 | 5 | INTERIM | 2020-02-20 | Equity Share |
| 2019-08-06 | 3 | FINAL | Equity Share | |
| 2018-08-02 | 1 | FINAL | Equity Share | |
| 2017-07-27 | 1 | FINAL | Equity Share | |
| 2015-07-22 | 1 | FINAL | Equity Share | |
| 2014-07-18 | 2.5 | FINAL | Equity Share | |
| 2013-10-31 | 2.5 | INTERIM | 2013-11-01 | Equity Share |
| 2013-07-19 | 2 | FINAL | Equity Share | |
| 2012-11-01 | 2 | INTERIM | 2012-11-02 | Equity Share |
| 2012-07-20 | 1.2 | FINAL | Equity Share | |
| 2012-02-07 | 1 | INTERIM | 2012-02-08 | Equity Share |
| 2011-11-03 | 1 | INTERIM | 2011-11-07 | Equity Share |
| 2011-07-18 | 1.2 | FINAL | Equity Share | |
| 2011-02-01 | 1 | INTERIM | 2011-02-02 | Equity Share |
| 2010-10-28 | 1 | INTERIM | 2010-10-29 | Equity Share |
| 2010-07-16 | 1 | FINAL | Equity Share | |
| 2010-01-27 | 4 | INTERIM | 2010-01-28 | Equity Share |
| 2009-10-30 | 5 | INTERIM | 2009-11-03 | Equity Share |
| 2009-07-20 | 4 | FINAL | Equity Share | |
| 2009-01-27 | 3 | INTERIM | 2009-01-28 | Equity Share |
| 2008-11-07 | 4 | INTERIM | 2008-11-10 | Equity Share |
| 2008-07-14 | 4.5 | FINAL | Equity Share | |
| 2007-11-06 | 3.5 | INTERIM | 2007-11-07 | Equity Share |
| 2007-07-10 | 4 | FINAL | Equity Share | |
| 2006-11-02 | 3.5 | INTERIM | 2006-11-03 | Equity Share |
| 2006-07-18 | 3 | FINAL | Equity Share | |
| 2005-11-09 | 2.5 | INTERIM | 2005-11-10 | Equity Share |
| 2005-09-13 | 3 | FINAL | Equity Share | |
| 2004-11-04 | 5 | INTERIM | 2004-11-05 | Equity Share |
| 2004-07-02 | 6 | INTERIM | 2004-07-05 | Equity Share |
| 2003-11-07 | 5 | INTERIM | 2003-11-10 | Equity Share |
| 2003-07-24 | 9 | FINAL | Equity Share |
| Ex-Date | Old FV | New FV | Record Date |
|---|---|---|---|
| 2022-01-10 | 2 | 1 | 2022-01-11 |
| 2010-03-22 | 10 | 2 | 2010-03-23 |
Insider & Institutional Activity
- Bulk Block Deals
- Insider Trading & SAST
Client name |
Deal Type |
Date |
Action |
Avg. price |
Quantity |
Exchange |
|---|---|---|---|---|---|---|
| Usha Madhukar Chandurkar | Bulk | 2024-12-18 |
Sell |
1,501.52 | 4,000,000 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-11-14 |
Purchase |
867.55 | 158,841 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-11-14 |
Sell |
867.55 | 158,841 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-11-03 |
Purchase |
927.15 | 158,842 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-11-03 |
Sell |
927.15 | 158,842 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-25 |
Purchase |
900.35 | 148,105 | BSE |
| Ishares Msci India Small-Cap Etf | Block | 2022-10-25 |
Purchase |
900.35 | 68,372 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-25 |
Sell |
900.35 | 148,105 | BSE |
| Ishares India Sc Mauritius Company | Block | 2022-10-25 |
Sell |
900.35 | 68,372 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-17 |
Purchase |
889.45 | 232,725 | BSE |
| Ishares Msci India Small-Cap Etf | Block | 2022-10-17 |
Purchase |
889.45 | 34,160 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-17 |
Sell |
889.45 | 232,725 | BSE |
| Ishares India Sc Mauritius Company | Block | 2022-10-17 |
Sell |
889.45 | 34,160 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-11 |
Purchase |
912.05 | 170,676 | BSE |
| Ishares Msci India Small-Cap Etf | Block | 2022-10-11 |
Purchase |
912.05 | 25,053 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-11 |
Sell |
912.05 | 170,676 | BSE |
| Ishares India Sc Mauritius Company | Block | 2022-10-11 |
Sell |
912.05 | 25,053 | BSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-10-03 |
Purchase |
915.00 | 170,778 | NSE |
| Ishares Msci India Small-Cap Etf | Block | 2022-10-03 |
Purchase |
915.00 | 25,067 | NSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-10-03 |
Sell |
915.00 | 170,778 | NSE |
| Ishares India Sc Mauritius Company | Block | 2022-10-03 |
Sell |
915.00 | 25,067 | NSE |
| Ishares Core Msci Emerging Markets Etf | Block | 2022-09-19 |
Purchase |
861.10 | 221,724 | BSE |
| Ishares Msci India Small-Cap Etf | Block | 2022-09-19 |
Purchase |
861.10 | 32,263 | BSE |
| Ishares Core Emerging Markets Mauritius Co | Block | 2022-09-19 |
Sell |
861.10 | 221,724 | BSE |
| Ishares India Sc Mauritius Company | Block | 2022-09-19 |
Sell |
861.10 | 32,263 | BSE |
| Ishares Core Msci Total International Stock Etf | Block | 2022-05-04 |
Purchase |
1,010.40 | 191,293 | BSE |
| Ishares Core Total International Stock Mauritius Co | Block | 2022-05-04 |
Sell |
1,010.40 | 191,293 | BSE |
| Integrated Core Strategies (Asia) Pte. Ltd. | Bulk | 2021-11-30 |
Purchase |
2,103.52 | 2,546,497 | NSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-10-20 |
Purchase |
2,342.15 | 68,134 | BSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-10-20 |
Sell |
2,342.15 | 68,134 | BSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-10-11 |
Purchase |
2,334.70 | 68,135 | BSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-10-11 |
Sell |
2,334.70 | 68,135 | BSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-10-04 |
Purchase |
2,423.60 | 70,051 | NSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-10-04 |
Sell |
2,423.60 | 70,051 | NSE |
| Ishares Msci Emerging Markets Etf | Block | 2021-09-23 |
Purchase |
2,429.55 | 69,352 | BSE |
| Ishares Emerging Markets Index Mauritius Co | Block | 2021-09-23 |
Sell |
2,429.55 | 69,352 | BSE |
| Goldman Sachs Funds Goldman Sachs India Equity Portfolio | Bulk | 2021-09-02 |
Purchase |
2,531.90 | 927,874 | BSE |
| Goldman Sachs India Fund Limited | Bulk | 2021-09-02 |
Sell |
2,531.90 | 927,874 | BSE |
| Goldman Sachs Funds Goldman Sachs India Equity Portfolio | Block | 2021-09-02 |
Purchase |
2,531.90 | 927,874 | BSE |
| Goldman Sachs India Fund Limited | Block | 2021-09-02 |
Sell |
2,531.90 | 927,874 | BSE |
| Ishares Emerging Markets Min Vol Factor Etf | Block | 2021-06-23 |
Purchase |
2,003.70 | 99,178 | BSE |
| Ishares Emerging Markets Minimum Volatility Mauritius Co | Block | 2021-06-23 |
Sell |
2,003.70 | 99,178 | BSE |
| Ishares Emerging Markets Min Vol Factor Etf | Block | 2021-06-15 |
Purchase |
2,095.05 | 99,179 | BSE |
| Ishares Emerging Markets Minimum Volatility Mauritius Co | Block | 2021-06-15 |
Sell |
2,095.05 | 99,179 | BSE |
| Goldman Sachs Investments Mauritius I Ltd | Bulk | 2020-11-27 |
Purchase |
2,173.10 | 69,473 | NSE |
| Bnp Paribas Arbitrage | Bulk | 2020-11-27 |
Purchase |
2,162.44 | 194 | NSE |
| Integrated Core Strategies (Asia) Pte. Ltd. | Bulk | 2020-11-27 |
Sell |
2,158.70 | 2,015,056 | NSE |
| Bnp Paribas Arbitrage | Bulk | 2020-11-27 |
Sell |
2,154.27 | 1,311,732 | NSE |
| Goldman Sachs Investments Mauritius I Ltd | Bulk | 2020-11-27 |
Sell |
2,173.45 | 675,065 | NSE |
| Kaygee Investments Pvt Ltd | Block | 2020-09-25 |
Purchase |
2,066.15 | 101,000 | BSE |
| Makers Laboratories Limited | Block | 2020-09-25 |
Sell |
2,066.15 | 101,000 | BSE |
| Axis Mutual Fund A/C Axis Long Term Equity Fund | Bulk | 2017-06-16 |
Sell |
453.64 | 1,108,795 | NSE |
| Franklin Templeton Investment Funds | Bulk | 2015-03-02 |
Purchase |
662.00 | 1,000,000 | NSE |
| Janus Contrarian Fund | Bulk | 2015-03-02 |
Sell |
662.00 | 1,000,000 | NSE |
| Exon Laboratories Private Limited | Block | 2013-12-18 |
Purchase |
675.00 | 170,000 | BSE |
| Premchand Gigalal Godha | Block | 2013-12-18 |
Sell |
675.00 | 170,000 | BSE |
| Capital Group - A/C Small Cap World Fnd Inc | Bulk | 2010-07-12 |
Sell |
299.00 | 1,609,221 | NSE |
| Capital Research &Amp; Management Company A/C New World Fund In | Bulk | 2010-06-08 |
Sell |
275.42 | 1,078,838 | NSE |
| Kaygee Investments P Ltd | Block | 2007-10-12 |
Purchase |
696.00 | 839,100 | BSE |
| Exon Laboratories P Ltd | Block | 2007-10-12 |
Purchase |
696.00 | 532,200 | BSE |
| Premchand Godha | Block | 2007-10-12 |
Purchase |
696.00 | 151,102 | BSE |
| Chandurkar Investments Pvt Ltd | Block | 2007-10-12 |
Sell |
696.00 | 1,522,402 | BSE |
Client name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Avg. Price |
Regulation (Insider/SAST) |
Mode |
|---|---|---|---|---|---|---|---|---|
| Manish Kumar Jain | Designated Person |
Disposal |
2026-02-18 | 3,000 | 20,266 | 1,482.22 | Insider Trading | Market Sale |
| Kaygee Investments Pvt Ltd & Pacs | Promoter |
Acquisition |
2025-09-18 | 10,187,058 | 64,665,448 | SAST 29(2) | Merger | |
| Pawan Kothari | Designated Person |
Disposal |
2025-08-25 | 2,220 | 0 | 1,413.02 | Insider Trading | Market Sale |
| Mexin Medicaments Pvt. Ltd. | Promoter Group |
Disposal |
2025-08-21 | 14,058 | 0 | Insider Trading | Others | |
| Kaygee Investments Pvt. Ltd. | Promoter Group |
Acquisition |
2025-08-21 | 10,187,058 | 64,665,448 | Insider Trading | Others | |
| Paschim Chemicals Pvt. Ltd. | Promoter Group |
Disposal |
2025-08-21 | 10,173,000 | 0 | Insider Trading | Others | |
| Usha M Chandurkar | Promoter |
Disposal |
2025-01-06 | 4,000,000 | 113,467,472 | SAST 29(2) | Market | |
| Premchand Godha | Promoter |
Pledge |
2024-12-24 | 400,000 | 1,270,000 | SAST Reg31 | Release | |
| Premchand Godha | Promoter |
Pledge |
2024-12-24 | 20,000 | 1,250,000 | SAST Reg31 | Release | |
| Premchand Godha | Promoter |
Pledge |
2024-12-24 | 600,000 | 650,000 | SAST Reg31 | Release | |
| Premchand Godha | Promoter |
Pledge |
2024-12-24 | 550,000 | 1,200,000 | SAST Reg31 | Creation | |
| Premchand Godha | Promoter |
Pledge |
2024-12-24 | 600,000 | 600,000 | SAST Reg31 | Release | |
| Mr. Premchand Godha | Promoter |
Pledge |
2024-12-24 | 600,000 | 0 | SAST Reg31 | Release | |
| Nirmal Jain | Promoter |
Pledge |
2024-12-24 | 30,200 | 10,150 | SAST Reg31 | Release | |
| Nirmal Jain | Promoter |
Pledge |
2024-12-24 | 1,000 | 9,150 | SAST Reg31 | Release | |
| Nirmal Jain | Promoter |
Pledge |
2024-12-24 | 9,150 | 0 | SAST Reg31 | Release | |
| Mr. Nirmal Jain | Promoter |
Pledge |
2024-12-24 | 9,150 | 0 | SAST Reg31 | Release | |
| Mrs. Usha M. Chandurkar | Promoter Group |
Disposal |
2024-12-19 | 4,000,000 | 4,302,000 | 1,499.25 | Insider Trading | Market Sale |
| Hdfc Mutual Fund | Other |
Acquisition |
2024-09-20 | 5,123,142 | 22,933,381 | SAST 29(2) | Market | |
| Kotak Mahindra Mutual Fund | Other |
Acquisition |
2024-08-07 | 409,318 | 12,747,825 | SAST 29(1) | Market | |
| Paschim Chemicals Pvt. Ltd. | Promoter Group |
Acquisition |
2024-03-12 | 35,000 | 10,173,000 | 1,200.97 | Insider Trading | Market Purchase |
| Mr. Ajit Kumar Jain | Director |
Disposal |
2023-11-20 | 20,000 | 42,000 | 1,081.85 | Insider Trading | Market Sale |
| Hdfc Mutual Fund & Others | Other |
Acquisition |
2023-07-31 | 63,530 | 17,810,239 | SAST 29(2) | Market | |
| Mr. E. J. Babu (Former Designated Employee) | Other |
Disposal |
2022-09-19 | 2,000 | 14,000 | 874.38 | Insider Trading | Market Sale |
| Mrs. Usha Chandurkar | Promoter Group |
Acquisition |
2022-08-04 | 4,000,000 | 8,302,000 | Insider Trading | Inheritance | |
| Mrs. Usha Chandurkar | Promoter Group |
Acquisition |
2022-08-01 | 302,000 | 4,302,000 | Insider Trading | Inheritance | |
| Mr. A. K. Jain | Director |
Disposal |
2022-03-21 | 20,000 | 62,000 | 1,026.82 | Insider Trading | Market Sale |
About Ipca Laboratories Ltd
Stock PE (TTM)
Promoter Holding
Book Value
ROCE
ROE
Ipca Laboratories Ltd is a pharmaceutical company based in India. On October 19, 1949, the company was incorporated in Mumbai under the name The Indian Pharmaceutical Combine Association Limited. The company was named Ipca laboratories Ltd in 1964, and then it was changed to Ipca Laboratories Private Limited. However, in 1988, it was again changed back to Ipca Laboratories Ltd.
Ipca laboratories Ltd is listed on the Bombay Stock Exchange with the code 524494 and on the National Stock Exchange with the symbol IPCALAB. The company had a market capitalisation of Rs 22,016 crore on November 18, 2022.
Ipca Laboratories Ltd manufactures over 350 formulations and 80 active pharmaceutical ingredients (APIs). It has 17 manufacturing units across India, and its products are exported to 100 countries. Some APIs that Ipca Laboratories Ltd manufactures are Atenolol, Chloroquine phosphate, Chlorthalidone, Furosemide, and Hydroxychloroquine sulfate. The company has introduced a number of medicine brands, such as Zerodo, Perinorm, Tenoric, Lumerax, and Folitrax, to name a few. The subsidiary companies of Ipca laboratories Ltd are Ipca Pharmaceuticals Inc, Ipca laboratories (UK) Ltd, and Tonira Exports Ltd.
On November 17, 2022, Ipca Laboratories Ltd’s share price closed at Rs 867.80. The share prices of Ipca laboratories Ltd have risen by 52.29% over the past three years and fallen by 16.63% in the past 12 months. The share’s 52-week high was Rs 1,128.50, and the 52-week low was Rs 831.05 as of November 18, 2022.
In the third quarter of 2022, the company’s revenue was Rs 1,601 crore, which is 0.95% more than the previous quarter. The company had the best quarter in September 2021, with a profit of Rs 250 crore. The profit in the September quarter of 2022 was Rs 144 crore.
As of November 18, 2022, 46.29% of Ipca Laboratories Ltd’s shares are owned by the promoters, followed by mutual funds and foreign institutional investors with 29.71% and 10.55% company shares, respectively.
Premchand Godha is the chairman and managing director of the company, Ajit Kumar Jain is the joint managing director, and Pranay Godha and Prashant Godha are executive directors.
Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.
Ipca Laboratories share price as on 21 Sep 2026 is Rs. 2009.6. Over the past 6 months, the Ipca Laboratories share price has increased by 28.38% and in the last one year, it has increased by 53.26%. The 52-week low for Ipca Laboratories share price was Rs. 1251.6 and 52-week high was Rs. 2038.
48 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, 400067
Tel No. 91-22-66474444
Email investors:ipca.com ; ipca:ipca.com
MUFG Intime India Pvt Ltd
Tel No. 91-22-49186000
Email rnt.helpdesk:in.mpms.mufg.com
Independent Non Exe. Director
Independent Director
Managing Director & Chief Executive Officer
Executive Director
Independent Non Exe. Director
Company Sec. & Compli. Officer
Executive Chairman
Managing Director & CFO
Independent Director
524494
IPCALAB
INE571A01038
Aug
Ipca Laboratories Ltd FAQs
You can buy Ipca Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Ipca Laboratories Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 18, 2026 03:58 PM the closing price of Ipca Laboratories Ltd was Rs.2,009.60.
The latest PE ratio of Ipca Laboratories Ltd as of Sep 18, 2026 03:58 PM is 37.10
The latest PB ratio of Ipca Laboratories Ltd as of Sep 18, 2026 03:58 PM is 6.32
The 52-week high of Ipca Laboratories Ltd share price is Rs. 2,038.00 while the 52-week low is Rs. 1,251.60
According to analyst recommendations, Ipca Laboratories Ltd Share has a "Buy" rating for the long term.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 18, 2026 03:58 PM, the market cap of Ipca Laboratories Ltd stood at Rs. 50,984.36 Cr.
Market Outlook
View all-202606161502166115397.jpg)
India Investor Conference 2026 : India's Power Infrastructure Boom and Data Center Growth Opportunity
ICICI Securities Ltd - INZ000183631 At the India Investor Conference 2026, Kushal Desai, Chairman and Managing Director of APAR Industries, shared his perspective on the forces reshaping the global po...
India Investor Conference 2026 - Deep dive into the Electronics Manufacturing Industry
ICICI Securities Ltd - INZ000183631 How India’s Electronics Manufacturing Industry Is Moving Beyond Assembly to Become a Global Design and Engineering Hub At the India Investor Conference 2026, ...
India Investor Conference 2026 - Professor V. Kamakoti on Building a Technology Superpower Through Startups, Innovation and Deep Tech
ICICI Securities Ltd - INZ000183631 Speaking at the India Investor Conference 2026, Professor V. Kamakoti, Director, IIT Madras, shared his perspective on how academic institutions, industry leaders a...
India Investor Conference: Larsen & Toubro's Growth Strategy and India's Capex Future
ICICI Securities Ltd - INZ000183631 At the India Investor Conference 2026, R Shankar Raman, President, Whole-time Director and Chief Financial Officer of Larsen & Toubro, shared his views on India...
